Tag: RemeGen

Breakthroughs in Urothelial Carcinoma: New Insights from 2026 EAU Congress on Disitamab Vedotin

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors

Disitamab Vedotin Gains Approval in China for its Third Indication

In 2022, with an estimated 2.3 million new cases and nearly 700.000 deaths globally, breast cancer emerged as the most prevalent cancer after lung...

Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, said it will prioritize key research and development efforts to advance EO-3021 (SYSA1801), its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin 18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.

RC118, an antibody-drug conjugates or ADC being developed by RemeGen, a commercial-stage biotechnology company based in Yantai, China, has been granted two orphan drug...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for disitamab vedotin (previously known as RC48), for the second-line treatment of...

Data from a phase II study of disitamab vedotin (previously known as RC48) shows clinically meaningful results in the treatment of heavily pretreated patients...

The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application allowing Yantai (Shandong Province; China) -based biopharmaceutical company RemeGen...